Toray Industries, Inc.

Motohiro Shiraki

Kei Takahashi

Naoki Izumimoto

Katsuhiko Iseki

Yasuhiro Morita

Shunsuke Iwano

Shuji Udagawa

Tomoya Miyoshi

Yuji Osada

Tetsuro Koreeda

Masanori Murakami

Keiyu Oshida

Toshikazu Komagata

Hirozumi Takahashi

Masahiro Akimoto

Akihiro Ando

Eriko Higashi

Tsutomu Nogami

A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. A cyclic amine derivative represented by general formula or a pharmacologically acceptable salt thereof:  A method of treating neuropathic pain includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal. A method of treating fibromyalgia syndrome includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal.

Cyclic amine derivative and pharmaceutical use thereof

A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. The cyclic amine derivative is represented by formula, a prodrug thereof or a pharmacologically acceptable salt thereof: wherein A represents a group represented by Formula (IIa), (IIb) or (IIc): wherein

A crystal of (S,E)-2-(2,6-dichlorobenzamido)-5-[4-(methyl-pyrimidin-2-ylamino)phenyl-yl]pent-4-enoic acid has excellent chemical and physical stability, and a medical use thereof.

Crystals of glycine derivative and pharmaceutical use thereof

Crystalline particles of N-(17-cyclopropylmethyl-4,5&#x3b1;-epoxy-3,14-dihydroxy-morphinan-6&#x3b2;-yl)-phthalimide or a pharmaceutically acceptable salt thereof are disclosed. The crystalline particles have a particle diameter distribution in which a particle diameter (D50) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 50% is within a range of 1 to 30 &#x3bc;m, and a particle diameter (D90) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 90% is not more than 90 &#x3bc;m, which crystalline particles have a degree of crystallinity of not less than 80%. By the crystalline particles, bioavailability of the active substance may be increased while ensuring storage stability of the compound.

Crystalline micropowder particles

Growing community of inventors

Kamakura, Japan

Motohiro Shiraki